


**Listing of Claims:**

*This listing of claims replaces all prior versions, and listings, of claims in the captioned application.*

1. (Previously Presented) A method of inhibiting mutant HIV protease in a mammal infected with said mutant HIV protease, said method comprising the step of administering to said mammal a therapeutically effective amount of a compound having the formula



a N-oxide, salt, stereoisomeric form, racemic mixture, prodrug, ester or metabolite thereof, wherein

R<sub>1</sub> is hexahydrofuro[2,3-b]furan-2-yl, tetrahydrofuran-2-yl, oxazol-2-yl, thiazol-2-yl, pyridin-2-yl, or phenyl optionally substituted with one or more substituents independently selected from C<sub>1-6</sub>alkyl, hydroxy, amino, halogen, aminoC<sub>1-4</sub>alkyl and mono- or di(C<sub>1-4</sub>alkyl)amino;

R<sub>2</sub> is hydrogen or C<sub>1-6</sub>alkyl;

L is a direct bond, -O-, C<sub>1-6</sub>alkanediyl-O- or -O-C<sub>1-6</sub>alkanediyl;

R<sub>3</sub> is phenylC<sub>1-4</sub>alkyl;

R<sub>4</sub> is C<sub>1-6</sub>alkyl;

R<sub>5</sub> is hydrogen or C<sub>1-6</sub>alkyl;

R<sub>6</sub> is hydrogen or C<sub>1-6</sub>alkyl.

2. (Previously Presented) The method according to claim 1 wherein

R<sub>2</sub> is hydrogen;

R<sub>3</sub> is phenylmethyl;

R<sub>4</sub> is C<sub>1-4</sub>alkyl, preferably isobutyl;

R<sub>5</sub> is hydrogen or methyl;

R<sub>6</sub> is hydrogen or methyl.

3. (Previously Presented) The method according to claim 1 wherein R<sup>5</sup> is methyl or hydrogen and R<sup>6</sup> is hydrogen
4. (Previously Presented) The method according to claim 1 wherein both R<sup>5</sup> and R<sup>6</sup> are hydrogen.
5. (Currently Amended) The method according to claim 1 wherein -L-R<sup>1</sup> is -O-(hexahydrofuro[2,3-b]furan-yl), -O-tetrahydrofuran-yl, -O-methyl-(optionally substituted phenyl), -O-methyl-pyridinyl, -O-methyl-thiazolyl, -O-methyl-thiazolyl, -methyl-O-(optionally substituted phenyl) or optionally substituted phenyl.
6. (Previously Presented) A method of inhibiting mutant HIV protease in a mammal infected with said mutant HIV protease, said method comprising the step of administering to said mammal a therapeutically effective amount of a compound selected from the group consisting of:
- {3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
- {3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-carbamic acid thiazol-5-ylmethyl ester;
- {1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
- {1-benzyl-3-[(2-dimethylamino-benzothiazole-6-sulfonyl)-isobutyl-amino]-2-hydroxy-propyl}-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;
- {3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-carbamic acid benzyl ester;
- N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-(2,6-dimethyl-phenoxy)-acetamide;
- {3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-carbamic acid pyridin-3-ylmethyl ester;

3-amino-N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-methyl-benzamide;

N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-3-hydroxy-2-methyl-benzamide;

{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-carbamic acid tetrahydro-furan-3-yl ester;

N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-methyl-benzamide;

N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-2-(2,6-dimethyl-phenoxy)-acetamide;

N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-3-fluoro-2-methyl-benzamide;

N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-(4-aminomethyl-2,6-dimethyl-phenoxy)-acetamide;

{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-carbamic acid thiazol-5-ylmethyl ester;

3-amino-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-2-methyl-benzamide;

{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-carbamic acid tetrahydro-furan-3-yl ester;

N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-3-hydroxy-2-methyl-benzamide;

N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-(4-iodo-2,6-dimethyl-phenoxy)-acetamide;

2-(4-aminomethyl-2,6-dimethyl-phenoxy)-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-acetamide;

2-(4-amino-2,6-dimethyl-phenoxy)-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-acetamide;


N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-4-bromo-2-methyl-benzamide;

{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-  
carbamic acid oxazol-5-ylmethyl ester;  
4-amino-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-  
propyl}-3-hydroxy-2-methyl-benzamide; and  
or a salt, or a stereoisomeric form thereof.

7. (Previously Presented) The method according to claim 1 wherein the mutant HIV protease has at least one mutation at a position selected from 10, 71 and 84.

8. (Previously Presented) The method according to claim 1 wherein the fold resistance of the mutant HIV protease for the compound described in claim 1 ranges between 0.01 and 100.

9. (Original) A compound having the formula



a *N*-oxide, salt, stereoisomeric form, racemic mixture, prodrug, ester or metabolite thereof,  
wherein

R<sub>1</sub> is hexahydrofuro[2,3-b]furan-2-yl, tetrahydrofuran-2-yl, oxazol-2-yl, thiazol-2-yl, pyridin-2-yl, or phenyl  
optionally substituted with one or more substituents independently selected from C<sub>1-6</sub>alkyl,  
hydroxy, amino, halogen, aminoC<sub>1-4</sub>alkyl and mono- or di(C<sub>1-4</sub>alkyl)amino;

R<sub>2</sub> is hydrogen or C<sub>1-6</sub>alkyl;

L is a direct bond, -O-, C<sub>1-6</sub>alkanediyl-O- or -O-C<sub>1-6</sub>alkanediyl;

R<sub>3</sub> is phenylC<sub>1-4</sub>alkyl;

R<sub>4</sub> is C<sub>1-6</sub>alkyl;

R<sub>5</sub> is hydrogen or C<sub>1-6</sub>alkyl;

R<sub>6</sub> is hydrogen or C<sub>1-6</sub>alkyl;

provided that the compound is other than :

{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
carbamic acid benzyl ester;

{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
carbamic acid pyridin-3-ylmethyl ester;  
{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
carbamic acid thiazol-5-ylmethyl ester;  
{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-  
(2,6-dimethyl-phenoxy)-acetamide;  
3-amino- {(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-  
hydroxypropyl}-2-methyl-benzamide;  
4-amino- {(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-  
hydroxypropyl}-2-methyl-benzamide;  
5-amino- {(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-  
hydroxypropyl}-2-methyl-benzamide;  
N- {(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
2-methyl-benzamide;  
N- {(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
4-hydroxy-2-methyl-benzamide;  
N- {(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
3-hydroxy-2-methyl-benzamide; and  
{(1S,2R)-3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-  
carbamic acid (S)-(tetrahydrofuran-3-yl) ester.

10. (Original) A compound according to claim 9 wherein R<sup>1</sup> is hexahydrofuro[2,3-b]furanyl or oxazolyl.

11. (Original) A compound according to claim 9 wherein R<sub>1</sub> is hexahydrofuro[2,3-b]furanyl, tetrahydrofuranyl, oxazolyl, thiazolyl, and L is a direct bond.

12. (Original) A compound according to claim 9 wherein R<sub>1</sub> is hexahydrofuro[2,3-b]furanyl, oxazolyl, thiazolyl, pyridinyl, or phenyl optionally substituted with one or more substituents

independently selected from C<sub>1-6</sub>alkyl, hydroxy, amino, halogen, aminoC<sub>1-4</sub>alkyl and mono-or di(C<sub>1-4</sub>alkyl)amino; and L is -O-.

13. (Currently Amended) A compound ~~e~~ according to claim 9 ~~wherein~~ wherein R<sub>1</sub> is hexahydrofuro[2,3-b]furanyl, tetrahydrofuranyl, oxazolyl, or phenyl substituted with one or more substituents independently selected from C<sub>1-6</sub>alkyl, hydroxy, amino, halogen, aminoC<sub>1-4</sub>alkyl and mono-or di(C<sub>1-4</sub>alkyl)amino; and L is C<sub>1-6</sub>alkanediyl-O- whereby the -O- is attached to the nitrogen of the amide.

14. (Original) A compound according to claim 9 wherein R<sub>1</sub> is hexahydrofuro[2,3-b]furanyl, tetrahydrofuranyl, oxazolyl, thiazolyl, pyridinyl, or phenyl optionally substituted with one or more substituents independently selected from hydroxy, amino, halogen, aminoC<sub>1-4</sub>alkyl and mono-or di(C<sub>1-4</sub>alkyl)amino; and L is -O-C<sub>1-6</sub>alkanediyl whereby -O- is attached to the R<sup>1</sup> group.

15. (Previously Presented) A compound according to claim 9 wherein at least one of R<sub>5</sub> and R<sub>6</sub> is C<sub>1-6</sub>alkyl.

16. (Previously Presented) A compound according to claim 9 wherein R<sup>2</sup> is hydrogen; R<sup>3</sup> is phenylmethyl; R<sup>4</sup> is C<sub>1-4</sub>alkyl.

17. (Currently Amended) A compound ~~according to claim 9~~ having the formula  
{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-  
carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;  
{1-benzyl-3-[(2-dimethylamino-benzothiazole-6-sulfonyl)-isobutyl-amino]-2-hydroxy-propyl}-  
carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;  
N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-  
2-(2,6-dimethyl-phenoxy)-acetamide;  
N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-3-fluoro-  
2-methyl-benzamide;

N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-(4-aminomethyl-2,6-dimethyl-phenoxy)-acetamide;  
{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-carbamic acid thiazol-5-ylmethyl ester;  
3-amino-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-2-methyl-benzamide;  
{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-carbamic acid tetrahydro-furan-3-yl ester;  
N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-3-hydroxy-2-methyl-benzamide;  
N-{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-2-(4-iodo-2,6-dimethyl-phenoxy)-acetamide;  
2-(4-aminomethyl-2,6-dimethyl-phenoxy)-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-acetamide;  
2-(4-amino-2,6-dimethyl-phenoxy)-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-acetamide;  
N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-4-bromo-2-methyl-benzamide;  
{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-carbamic acid oxazol-5-ylmethyl ester;  
4-amino-N-{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-3-hydroxy-2-methyl-benzamide; or  
a salt thereof, or a stereoisomeric form thereof.

18. (Currently Amended) A compound ~~that is~~ according to claim 9, selected from the group consisting of:

{3-[(2-amino-benzothiazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl}-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;  
~~{1-benzyl-2-hydroxy-3-[isobutyl-(2-methylamino-benzothiazole-6-sulfonyl)-amino]-propyl}-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester;~~

~~{1-benzyl-3-[(2-dimethylamino-benzothiazole-6-sulfonyl)-isobutyl-amino]-2-hydroxy-propyl}-~~  
~~carbamic acid-hexahydro-furo[2,3-b]furan-3-yl ester;~~  
or a salt or stereoisomeric form thereof.

19. (New) The method according to claim 2 wherein the mutant HIV protease has at least one mutation at a position selected from 10, 71 and 84.

20. (New) The method according to claim 3 wherein the mutant HIV protease has at least one mutation at a position selected from 10, 71 and 84.

21. (New) The method according to claim 4 wherein the mutant HIV protease has at least one mutation at a position selected from 10, 71 and 84.

22. (New) The method according to claim 5 wherein the mutant HIV protease has at least one mutation at a position selected from 10, 71 and 84.

23. (New) The method according to claim 6 wherein the mutant HIV protease has at least one mutation at a position selected from 10, 71 and 84.